FundaciÃ³n JimÃ©nez Diaz Trials

FundaciÃ³n JimÃ©nez Diaz	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Guerrero, Tatiana Hernandez

KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors

Recruiting

1/2

104

Europe, US

BI-1910, Pembrolizumab

BioInvent International AB, Merck Sharp & Dohme LLC

Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma

07/27

11/28

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting

1/2

576

Europe, US, RoW

MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy

Merus N.V.

Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

03/26

03/27

TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting

1/2

225

Europe, US

TNG462, Pembrolizumab, Keytruda

Tango Therapeutics, Inc.

Locally Advanced Solid Tumor

05/26

09/26

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting

200

Europe, Canada, Japan, US, RoW

M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Colorectal Cancer

02/26

ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting

275

Europe, US, RoW

ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin

Enliven Therapeutics

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer

01/27

07/28

SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting

1006

Europe, US, RoW

sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin

Seagen, a wholly owned subsidiary of Pfizer

Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms

08/26

05/28

NCT06421935: M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Recruiting

Europe, Japan, US, RoW

M9466, HRS-1167;, Tuvusertib, Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004, Abiraterone acetate, Abiraterone, Prednisone/Prednisolone

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Advanced Solid Tumor

03/26

MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting

540

Europe, Canada, Japan, US

LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil

Eli Lilly and Company, Loxo Oncology, Inc.

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

03/29

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25

TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting

241

Europe, US

TOS-358

Totus Medicines

Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer

12/25

NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting

Europe, US, RoW

KIN-3248

Kinnate Biopharma

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma

06/26

09/26

ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting

198

Europe, US, RoW

ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1

Enliven Therapeutics

HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

07/26

Lubomirov, Rubin

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

NCT05063318: Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration

PharmaMar

Advanced Solid Tumors

11/22

12/22

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Guerrero, Tatiana Hernandez

KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors

Recruiting

1/2

104

Europe, US

BI-1910, Pembrolizumab

BioInvent International AB, Merck Sharp & Dohme LLC

Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma

07/27

11/28

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting

1/2

576

Europe, US, RoW

MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy

Merus N.V.

Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

03/26

03/27

TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting

1/2

225

Europe, US

TNG462, Pembrolizumab, Keytruda

Tango Therapeutics, Inc.

Locally Advanced Solid Tumor

05/26

09/26

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting

200

Europe, Canada, Japan, US, RoW

M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Colorectal Cancer

02/26

ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting

275

Europe, US, RoW

ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin

Enliven Therapeutics

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer

01/27

07/28

SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting

1006

Europe, US, RoW

sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin

Seagen, a wholly owned subsidiary of Pfizer

08/26

05/28

NCT06421935: M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Recruiting

Europe, Japan, US, RoW

M9466, HRS-1167;, Tuvusertib, Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004, Abiraterone acetate, Abiraterone, Prednisone/Prednisolone

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Advanced Solid Tumor

03/26

MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting

540

Europe, Canada, Japan, US

LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil

Eli Lilly and Company, Loxo Oncology, Inc.

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

03/29

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25

TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting

241

Europe, US

TOS-358

Totus Medicines

Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer

12/25

NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting

Europe, US, RoW

KIN-3248

Kinnate Biopharma

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma

06/26

09/26

ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting

198

Europe, US, RoW

ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1

Enliven Therapeutics

HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

07/26

Lubomirov, Rubin

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

NCT05063318: Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration

PharmaMar

Advanced Solid Tumors

11/22

12/22

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25



	Diseases Companies Products Productz Mechanisms of Action Sites